(MedPage Today) — CHICAGO — A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III QWINT development program found.
In QWINT-1, there was a similar HbA1c reduction with…
(MedPage Today) — CHICAGO — A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III QWINT development program found.
In QWINT-1, there was a similar HbA1c reduction with…
